Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Solid Tumors
NCT04056910Phase 2Completed
- Start
- Sep 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ivosidenib in solid tumor, glioma. Started Sep 2021; status: completed.
02
Drugs
ivosidenib
03
Conditions
solid tumorglioma
Beyond the preview
Go deeper on NCT04056910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056910.